Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Medical Equipment

CU2:GR

4.031 EUR 0.046 1.13%

As of 15:44:38 ET on 05/22/2015.

Snapshot for Cerus Corp (CU2)

Open: 4.049 Day's Range: 4.021 - 4.112 Volume: 0
Previous Close: 4.077 52wk Range: 2.563 - 6.000 1-Yr Rtn: +34.55%

Stock Chart for CU2

No chart data available.
  • CU2:GR 4.044
  • 1D
  • 1M
  • 1Y
4.077
Interactive CU2 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CU2

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.5600
Est. PEG Ratio -
Market Cap (M EUR) 384.44
Shares Outstanding (M) 95.37
30 Day Average Volume 93
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/31/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CU2

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CU2

Cerus Corporation develops systems designed to enhance the safety of blood transfusions. The Company's systems inactivate pathogens in blood components and inactivate white blood cells, which are responsible for a variety of adverse transfusion reactions. Cerus' platform technologies prevent viral, bacterial, and cellular replication.

William Mariner Greenman "Obi"President/CEOChrystal N MenardChief Legal Ofcr/Gen Cnsl
Caspar HogeboomPres:Cerus EuropeLaurence M CorashSenior VP/Chief Medical Ofcr/Co-Founder
More Company Profile & Key Executives for CU2

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil